Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition

XOMA Royalty will acquire Mural Oncology under an Irish High Court‑sanctioned scheme for a final cash consideration of $2.035 per share (Additional Price Per Share $0.000), per the August 20, 2025 Transaction Agreement; closing is expected in early December 2025 subject to conditions and court approval. The deal affects a biotech advancing nemvaleukin alfa and IL‑18/IL‑12 programs and remains subject to Irish takeover disclosure rules; MURA last traded at $2.02 (down 3.49%) on volume of ~2.21M vs. average ~167K and a 52‑week range of $0.95–$4.74.

Analysis

Market structure: The immediate winners are existing MURA shareholders and merger arbitrage funds who can capture the $2.035 cash consideration; given MURA trades at $2.02 with heavy volume (2.21M vs avg 167k) the spread-to-deal is ~0.75% implying a tiny arb premium after costs. XOMA shareholders are potential losers if the acquisition strains XOMA's balance sheet or reduces royalty exposure, so expect differentiated flows between small-cap biotech equities and specialty royalty vehicles. Broader market impact is negligible on rates/FX/commodities; expect idiosyncratic option and equity flow in small-cap biotech and arbitrage desks only.

Risk assessment: Tail risks include Irish High Court rejection, regulatory disclosure-triggered competing bids, or XOMA financing issues — any failure could drop MURA toward prior lows (52‑week low $0.95) or produce a competing bid >$2.20 and push price up; assign ~95% close probability but model a 5% deal-fail tail. Time horizons: immediate (days) for arb capture and volatility, short-term (weeks) for takeover disclosures and hearing calendar, long-term (quarters) for pipeline value realization (nemvaleukin/IL-18/IL-12). Hidden dependencies: XOMA’s funding sources, escrow/indemnities and Irish scheme timing; these are binary catalysts that will dominate returns.

Trade implications: Primary direct play is merger arbitrage: small, capital-efficient long MURA positions sized to capture ~0.5–1.0% portfolio exposure until early Dec 2025 close, using protective puts or collars because gross spread is sub‑1%. Pair trade: long MURA arb vs slight short in XOMA equity (or reduce XOMA exposure) if acquirer financing looks dilutive; prefer hedges (60‑90 day puts) over naked shorts given asymmetry. Options: consider buying a 60‑90 day put (strike ~$1.90) to cap downside, or sell short-dated calls to finance puts if liquidity allows; act within next 5 trading days and trim on any price >$2.05 or upon court sanction.

Contrarian angles: Consensus treats this as a done deal with minimal upside; that underprices both the deal-fail fat tail and potential strategic upside if the pipeline is re-opened — a failed deal could reveal rerating to $3–5 if MURA secures a better buyer or positive trial news. Conversely, if spread compresses below transaction costs (<1.0%), the arb is overdone and not worth execution. Historical parallels: small biotech cash schemes close >90% but Irish scheme mechanics can delay cash-out by weeks; unintended consequence — takeover disclosure rules could spark short-term volatility from >1% holders trading, creating entry points for tactical adds.

Key Decisions for Investors

• Establish a small merger-arb long in MURA equal to 0.5–1.0% of portfolio by buying up to $2.03; target exit at $2.035–2.05 on deal close (early Dec 2025) and cap loss with a hard stop at $1.88 or by buying a 60‑90 day $1.90 put if cost <3% of position value.
• If options/liquidity permit, implement a collar through Dec 2025: buy MURA shares, buy $1.90 puts and sell ~$2.05 calls to fund puts; aim for net premium ≤1.0% to keep arb capture economically attractive.
• Do NOT allocate >1.0% to MURA arb unless gross spread >1.5% after fees; if spread compresses below 1.0%, close position—transaction costs will negate upside.
• Monitor Irish High Court hearing dates and any 1%+ holder disclosure filings over the next 30 days; if a competing bid >$2.20 emerges, increase MURA exposure up to 1.5% and reprice upside; if XOMA announces material financing/dilution concerns, initiate a tactical 0.5% short of XOMA equity within 48 hours.